A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.

Human genetic variation contributes to differences in susceptibility to HIV-1 infection. To search for novel host resistance factors, we performed a genome-wide association study (GWAS) in hemophilia patients highly exposed to potentially contaminated factor VIII infusions. Individuals with hemophilia A and a documented history of factor VIII infusions before the introduction of viral inactivation procedures (1979-1984) were recruited from 36 hemophilia treatment centers (HTCs), and their genome-wide genetic variants were compared with those from matched HIV-infected individuals. Homozygous carriers of known CCR5 resistance mutations were excluded. Single nucleotide polymorphisms (SNPs) and inferred copy number variants (CNVs) were tested using logistic regression. In addition, we performed a pathway enrichment analysis, a heritability analysis, and a search for epistatic interactions with CCR5 Δ32 heterozygosity. A total of 560 HIV-uninfected cases were recruited: 36 (6.4%) were homozygous for CCR5 Δ32 or m303. After quality control and SNP imputation, we tested 1 081 435 SNPs and 3686 CNVs for association with HIV-1 serostatus in 431 cases and 765 HIV-infected controls. No SNP or CNV reached genome-wide significance. The additional analyses did not reveal any strong genetic effect. Highly exposed, yet uninfected hemophiliacs form an ideal study group to investigate host resistance factors. Using a genome-wide approach, we did not detect any significant associations between SNPs and HIV-1 susceptibility, indicating that common genetic variants of major effect are unlikely to explain the observed resistance phenotype in this population.

[1]  John H. Morris,et al.  Global landscape of HIV–human protein complexes , 2011, Nature.

[2]  Christopher T. Jones,et al.  A diverse array of gene products are effectors of the type I interferon antiviral response , 2011, Nature.

[3]  P. Visscher,et al.  Estimating missing heritability for disease from genome-wide association studies. , 2011, American journal of human genetics.

[4]  K. Shianna,et al.  Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population , 2011, AIDS.

[5]  P. Visscher,et al.  GCTA: a tool for genome-wide complex trait analysis. , 2011, American journal of human genetics.

[6]  Kenny Q. Ye,et al.  Mapping copy number variation by population scale genome sequencing , 2010, Nature.

[7]  Jack T Stapleton,et al.  The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation , 2010, Science.

[8]  G. Abecasis,et al.  MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes , 2010, Genetic epidemiology.

[9]  A. Telenti,et al.  Genomic approaches to the study of HIV‐1 acquisition. , 2010, The Journal of infectious diseases.

[10]  D. Goldstein,et al.  Determinants of protection among HIV‐exposed seronegative persons: an overview. , 2010, The Journal of infectious diseases.

[11]  K. Shianna,et al.  Host Genetics and HIV-1: The Final Phase? , 2010, PLoS pathogens.

[12]  Ayellet V. Segrè,et al.  Common Inherited Variation in Mitochondrial Genes Is Not Enriched for Associations with Type 2 Diabetes or Related Glycemic Traits , 2010, PLoS genetics.

[13]  Elizabeth T. Cirulli,et al.  Common Genetic Variation and the Control of HIV-1 in Humans , 2009, PLoS genetics.

[14]  Judy H. Cho,et al.  Finding the missing heritability of complex diseases , 2009, Nature.

[15]  Amy S. Espeseth,et al.  Host Cell Factors in HIV Replication: Meta-Analysis of Genome-Wide Studies , 2009, PLoS pathogens.

[16]  Manuel A. R. Ferreira,et al.  Practical aspects of imputation-driven meta-analysis of genome-wide association studies. , 2008, Human molecular genetics.

[17]  Joseph T. Glessner,et al.  PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. , 2007, Genome research.

[18]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[19]  R. Baggaley,et al.  Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis , 2006, AIDS.

[20]  John Novembre,et al.  The Geographic Spread of the CCR5 Δ32 HIV-Resistance Allele , 2005, PLoS biology.

[21]  S. Darby,et al.  The impact of HIV on mortality rates in the complete UK haemophilia population , 2004, AIDS.

[22]  J. Goedert,et al.  High frequency of CCR5-delta32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1. , 2003, Gastroenterology.

[23]  J. Morgenthaler.  Securing viral safety for plasma derivatives. , 2001, Transfusion medicine reviews.

[24]  J. Goedert,et al.  Characterization of high-risk HIV-1 seronegative hemophiliacs. , 2001, Clinical immunology.

[25]  J. Barretina,et al.  Evaluation of the putative role of C‐C chemokines as protective factors of HIV‐1 infection in seronegative hemophiliacs exposed to contaminated hemoderivatives , 2000, Transfusion.

[26]  R. Kaiser,et al.  Protection against parenteral HIV-1 infection by homozygous deletion in the C-C chemokine receptor 5 gene. , 1999, AIDS.

[27]  R. Koup,et al.  A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness. , 1998, The Journal of infectious diseases.

[28]  Luc Montagnier,et al.  HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene , 1998, The Lancet.

[29]  J. Clegg,et al.  Global distribution of the CCR5 gene 32-basepair deletion , 1997, Nature Genetics.

[30]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[31]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[32]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[33]  J J Goedert,et al.  HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. , 1994, Journal of acquired immune deficiency syndromes.

[34]  M. A. Lamb,et al.  Viral safety of clotting factor concentrates. , 1993, Seminars in thrombosis and hemostasis.

[35]  A. Thompson,et al.  Treatment type and amount influenced human immunodeficiency virus seroprevalence of patients with congenital bleeding disorders. , 1991, Blood.

[36]  C. Pegelow,et al.  Transmission of Human Immunodeficiency Virus Type 1 by Dry‐Heated Clotting Factor Concentrates 1 , 1990, Vox sanguinis.

[37]  L. Kingsley,et al.  1986 update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with hemophilia A and B , 1987 .

[38]  A. Goudeau,et al.  Immunologic and virologic status of multitransfused patients: role of type and origin of blood products. By the AIDS-Hemophilia French Study Group. , 1985, Blood.